Meroni P L, Harris E N, Brucato A, Tincani A, Barcellini W, Vismara A, Balestrieri G, Hughes G R, Zanussi C
Clin Exp Immunol. 1987 Mar;67(3):484-91.
In a series of 42 positive sera, anti-mitochondrial type M5 antibodies (AMA-M5) were found most frequently in patients with SLE (24) and SLE-like syndromes. Patients with AMA-M5 displayed a higher prevalence of thrombocytopenia, thrombosis, biological false positive seroreactions for syphilis, lupus-like anticoagulant activity and anti-cardiolipin antibodies in comparison with a group of 43 SLE AMA-M5 negative patients. The strong association between anti-phospholipid and AMA-M5 antibodies cannot be explained entirely by cross-reactivity between these two groups of antibodies, as indicated by absorption experiments and studies using affinity purified antibody preparations. However, cardiolipin liposomes were able to reduce partially the titres of AMA-M5 sera, suggesting that a small population of AMA-M5 antibodies exists that cross-reacts with cardiolipin. The existence of this population was further substantiated by our demonstration that an IgM monoclonal antibody, from a patient with Waldenström's macroglobulinaemia, displayed both anti-cardiolipin and AMA-M5 activity, and AMA-M5 activity was completely inhibited by cardiolipin.
在一系列42份阳性血清中,抗线粒体M5型抗体(AMA-M5)最常见于系统性红斑狼疮(SLE)患者(24例)和类SLE综合征患者。与43例AMA-M5阴性的SLE患者相比,AMA-M5患者血小板减少、血栓形成、梅毒生物学假阳性血清反应、狼疮样抗凝活性和抗心磷脂抗体的患病率更高。如吸收实验和使用亲和纯化抗体制剂的研究所表明,抗磷脂抗体与AMA-M5抗体之间的强关联不能完全用这两组抗体之间的交叉反应来解释。然而,心磷脂脂质体能够部分降低AMA-M5血清的滴度,这表明存在一小部分与心磷脂发生交叉反应的AMA-M5抗体。我们证明,来自一名瓦尔登斯特伦巨球蛋白血症患者的IgM单克隆抗体同时具有抗心磷脂和AMA-M5活性,且AMA-M5活性被心磷脂完全抑制,这进一步证实了这部分抗体的存在。